
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc. is poised for positive momentum due to the anticipated readouts from its clinical trials, particularly in the treatment of lupus nephritis (LN) and systemic lupus erythematosus (SLE), with management expressing confidence in a favorable outcome. The product candidate, ADI-001, distinguishes itself from traditional autologous CAR-T therapies by demonstrating comparable efficacy while offering a superior safety profile and off-the-shelf scalability, eliminating the need for leukapheresis. These attributes position ADI-001 as a competitive player in the CAR-T therapy market, potentially making it a first-choice treatment option.
Bears say
Adicet Bio Inc is projected to incur a net loss of $1.13 per share in 2025, with various risks including negative clinical data, slower clinical development timelines, and potential regulatory approval setbacks. The company faces challenges with delays in clinical trial initiation and unexpected safety issues, which could hinder the success of its product candidates, such as ADI-001 and ADI-270. Additionally, the reliance on external financing until achieving cash flow positivity poses a long-term dilution risk that could affect shareholders negatively.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares